Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)

BACKGROUND: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety in the Phase 3 DEFINE and CONFIRM trials. OBJECTIVE: To evaluate delayed-release DMF in newly diagnosed relapsing–remitting multiple sclerosis (RRMS) patients, in a post-hoc analysis of integrated data from DEFINE a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Ralf, Giovannoni, Gavin, Phillips, J Theodore, Fox, Robert J, Zhang, Annie, Meltzer, Leslie, Kurukulasuriya, Nuwan C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361464/
https://www.ncbi.nlm.nih.gov/pubmed/24990854
http://dx.doi.org/10.1177/1352458514537013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361464/
https://www.ncbi.nlm.nih.gov/pubmed/24990854
http://dx.doi.org/10.1177/1352458514537013

Ejemplares similares